Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

DUBLIN, Jan. 26, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its fourth-quarter and full-year 2020 financial results on February 25, 2021 after the market closes and members of its senior management team will host a conference call and webcast on February 26,...

Endo to Announce Fourth-Quarter and Full-Year 2020 Financial Results

Does Endo International (ENDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Endo International (ENDP)

DUBLIN, Dec. 18, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. EST. A live webcast and audio archive for the event will be available on...

Endo to Participate at J.P. Morgan 39th Annual Healthcare Conference

Endo (ENDP) reported earnings 30 days ago. What's next for the stock?

Why Is Endo (ENDP) Up 10.5% Since Last Earnings Report?

DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that the Company will participate in two investor conferences. Members of management will participate in the 2020 Bank of America Leveraged Finance Virtual Conference on Monday, November 30, 2020...

Endo to Participate In Upcoming Investor Conferences

Is Endo International (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

Can Value Investors Pick Endo International (ENDP) Stock?

Endo International plc (ENDP) CEO Blaise Coleman on Q3 2020 Results - Earnings Call Transcript

Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.

Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised

Endo (ENDP) delivered earnings and revenue surprises of 271.43% and 13.72%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Q3 Earnings and Revenues Top Estimates

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2020. "Our third-quarter 2020 results reflect growth in our Branded Pharmaceuticals segment as utilization of physician administered...

Endo Reports Third-Quarter 2020 Financial Results And Raises Full Year 2020 Financial Guidance

- Initiatives to Enable Company to Reinvest in Key Areas of Growth - DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the initiation of several strategic actions to further optimize the Company's operations and increase overall efficiency. These...

Endo Announces Strategic Actions to Further Position the Company for Long-Term Success

GOTHENBURG, Sweden, Nov. 2, 2020 /PRNewswire/ -- Isofol Medical AB (publ) ("Isofol"), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased to announce today a definitive license agreement with Endo Ventures Limited, a subsidiary of Endo International plc (NASDAQ: ENDP) plc, for...

Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

GOTHENBURG, Sweden, Nov. 2, 2020 /PRNewswire/ -- Isofol Medical AB (publ) ("Isofol"), (Nasdaq First North Premier Growth Market: ISOFOL) has today announced a definitive licensing agreement with Endo Ventures Limited, a subsidiary of Endo International plc. (NASDAQ: ENDP) for the...

Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common...

Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Endo International (ENDP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Endo (ENDP) is Poised to Beat Earnings Estimates Again

BioSpecifics Technologies

New York, New York--(Newsfile Corp. - October 21, 2020) - [DATELINE]Rowley Law PLLC is investigating potential securities law violations by BioSpecifics Technologies Corp. (NASDAQ: BSTC) and its board of directors concerning the proposed acquisition of the company by Endo International plc (NASDAQ: ENDP). Stockholders will receive $88.50 for each share of BioSpecifics Technologies stock that they hold. The transaction is valued at approximately $658 million and is expected to close in the fourth quarter of...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of BioSpecifics Technologies Corp.

Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.

Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M

Investors are fired up about Endo's planned acquisition of BioSpecifics.

Why Endo International and BioSpecifics Technologies Stocks Soared Today

News that Endo International PLC (NASDAQ: ENDP) would acquire BioSpecifics Technologies Corp.

Are BioSpecifics Shareholders Getting Enough in the Endo Buyout?

-- Endo to acquire BioSpecifics in an accretive all-cash transaction -- DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced it has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp. (NASDAQ: BSTC), a commercial-stage...

Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™

WILMINGTON, Del., Oct. 19, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo International plc (NASDAQ: ENDP) will acquire BioSpecifics for an estimated equity value of approximately...

BioSpecifics to be Acquired by Endo Pharmaceuticals

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced that data relevant to the use of Endo Aesthetics' Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women will be featured...

Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)

DUBLIN, Oct. 7, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2020 financial results on November 5, 2020 after the market closes and members of its senior management team will host a conference call and webcast on November 6, 2020 at 7:30am EST....

Endo to Announce Third Quarter 2020 Financial Results

Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

News for Endo International Stock (ENDP)